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Abstract
Telomerase plays a role in the unlimited replicative
capacity of the majority of cancer cells and provides a
potential anticancer target. The regulation of telome-
rase is complex but transcriptional control of its two
essential components, hTERC (RNA component) and
hTERT (reverse transcriptase component), is of major
importance. To investigate this further, we have used
the adenoviral protein, E1A, as a tool to probe poten-
tial pathways involved in the control of telomerase
transcription. The second exon of the adenoviral pro-
tein E1A activates both telomerase gene promoters in
transient transfections. The corepressor, C terminal
binding protein, is one of only two proteins known to
bind to this region, and we propose that E1A activates
both promoters by sequestering CtBP, thereby reliev-
ing repression. Activation by exon 2 of E1A involves
the SP1 sites in both promoters, and consistent with
this, SP1 and CtBP interact in coimmunoprecipitation
studies. Modulation of the chromatin environment has
been implicated in the regulation of hTERT transcrip-
tion and appears to involve the SP1 sites. CtBP can
be found within a histone-modifying complex and it
is possible that a CtBP complex, associating with the
SP1 sites, represses transcription from the telomerase
promoters by modifying chromatin structure.
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Introduction
Telomeres are specialized structures at the ends of chro-
mosomes consisting of tandem nucleotide repeats and
specific proteins (reviewed in Ref. [1]). They undergo short-
ening with successive rounds of DNA replication and, as
such, may act as a block to unlimited replication and may be
part of the signal involved in the onset of cellular senes-
cence [2,3]. The reverse transcriptase enzyme, telomerase,
is able to add telomeric repeats to the ends of chromo-
somes, thereby preventing telomeric attrition with repeated cell
division [4–6]. The majority of somatic cells do not express
telomerase, but it is found at high frequency across the spec-
trum of human cancers [7–9]. Artificial expression of telo-
merase in some cell types can increase telomere length and
replicative lifespan whereas inhibition of telomerase in immortal
cells results in telomere attrition and ultimately senescence or
cell death [10–16]. This has led to considerable interest in its
potential as an anticancer target.
The regulation of telomerase is complex, but transcriptional
control of its two essential components, hTERC (RNA compo-
nent) and hTERT (reverse transcriptase component), is of
major importance [17–20]. The promoter regions of both genes
have been characterized and a number of key transcription
factors have been identified (Figure 1) [19,21–26]. More re-
cently, modulation of the chromatin environment has been im-
plicated in the regulation of hTERT transcription [27–29].
An understanding of the regulation of telomerase is key to
its exploitation as an anticancer target. To investigate this
further, we have used the adenoviral protein, E1A (Figure 2),
as a tool to probe potential pathways involved in the control
of telomerase transcription. Expression of E1A alone is suffi-
cient to immortalize primary rodent cells [30], and can trans-
form them in cooperation with a second oncogene such as
E1B or activated ras [31,32]. The adenovirus 2/5 E1A gene
encodes two main proteins of 289 and 243 residues, which are
identical except for a 46–amino acid intervening sequence.
These proteins do not bind DNA directly but exert their ef-
fects by binding to a number of different cellular proteins that
are involved in the control of gene expression and cell growth.
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These include transcriptional coactivators, corepressors,
and cell cycle regulatory proteins (reviewed in Refs.
[33,34]). A number of well-characterized mutants, which
disrupt these interactions, exist. Thus, in a system where
E1A modulates transcription from a particular promoter,
mutants, which abrogate that effect, identify potential regu-
latory cellular proteins. E1A interacts with the Rb family of
proteins. It targets three histone HAT-containing coactivator
proteins, p300, CBP, and PCAF, and inhibits their function.
It also targets components of the chromatin remodelling
complex, TRRAP (transactivation/transformation domain–
associated protein), and p400 as well as the corepressor
protein, C-terminal binding protein (CtBP). We demonstrate
that E1A 243R activates transcription from both telomerase
gene promoters. Activation is also seen with exon 2 of E1A
alone (amino acids 186–243) and this is dependent on an
intact CtBP-interacting domain (CID), identifying CtBP, as a
potential inhibitor of telomerase component expression.
Materials and Methods
Cell Culture, Transfections, and Luciferase Assay
All cell lines were routinely cultured in 75-cm2 flasks in
20 ml of medium supplemented with 10% fetal calf serum
(FCS), 2mML-glutamine, and penicillin (50U/ml) and strepto-
mycin (50 mg/ml). 5637 bladder carcinoma cells were main-
tained in RPMI 1640 and A549, lung cancer cells in DMEM
media. Cells were transfected at 50% to 80% confluence
using a Superfect Transfection Reagent (Qiagen, Crawly,
UK). Cells were incubated for 48 hours after transfection and
were lysed in Cell Culture Lysis Buffer (Promega, Madison,
WI), and the luciferase assay was performed with Luciferase
Assay Reagent (Promega).
All transient transfections were carried out in duplicate
and were repeated at least two to three times. Transfection
efficiencies were controlled, where possible, using a second
reporter, either the Great EscAPe SEAP system (Clontech,
Cowley, UK) or the Dual Luciferase Reporter Assay System
(Promega). Where this was not possible because the control
promoters were also affected by the cotransfected proteins
under investigation, cellular protein equivalents were used.
Transfection efficiency was indirectly assessed by checking
for expression of E1A with Western blot analysis. The mean
and standard errors are displayed for duplicates from repre-
sentative experiments.
Plasmids
pLhTERT1/9, pLhTERT24/25, and pLhTERT24/9 were
constructed by inserting PCR products in pGL-3 Basic (Pro-
mega). Details of primers can be obtained from the authors.
pLh2923, pLh1011, and pLh114 were constructed as pre-
viously described [35]. The E1A expression constructs have
been described [36]—pCMV-SP1 by Dr. R. Tijian (University
of California, Berkley, CA) and pCMV-SP3 by Dr. Guntram
Suske (Institut fur Molekularbiologie und Tumorforschung,
Marburg, Germany).
Site-Directed Mutagenesis
Site-d i rected mutagenesis was performed on
pLhTERT24/25 and pLhTERT24/9 using the QuickChange
Site-Directed Mutagenesis Kit by Stratagene (La Jolla, CA)
according to the manufacturer’s instructions. The mutations
generated and primers are described in Ref. [37].
Figure 1. The telomerase gene promoters. (A) Schematic representation of hTERT promoter including the core promoter, showing transcription factor binding
sites. (B) Schematic representation of hTERC core promoter.
Figure 2. The adenoviral protein, E1A. Schematic representation of the E1A
13S and 12S proteins showing the conserved regions and CID and E1A
expression plasmids.
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Western Blot Analysis
Proteins were separated by SDS-PAGE using the
NuPAGE system. The proteins were blotted onto Millipore
nitrocellulose membrane. Blots were probed with Santa Cruz
(Santa Cruz Biotechnology, Santa Cruz, CA) #430 E1A
(1:500) and equivalent loading was confirmed with ERK 1
(C-16) Santa Cruz #93 (1:3000). Detection was achieved
using the ECL (HRP) Western blot analysis system (Amer-
shamPharmaciaBiotech, Little Chalfont, UK).
Coimmune Precipitations
Cells were washed in ice-cold PBS and kept in an ice
bath. Whole Cell Lysis Buffer [Hepes, pH 7.5 (50 mM), NaCl
(150 mM), NP40 detergent 1%, NaF (10 mM), b-glycero-
phosphate (10 mM), sodium orthovanadate (1 mM), DTT
(1 mM), and protease inhibitor cocktail tablet (Roche, Lewes,
UK)] was added and cells were frozen in an ethanol and dry
ice bath before thawing on ice. Cells were scraped from
dishes and the freeze–thaw cycle was repeated. Cell debris
was removed by centrifugation at 13 krpm for 10 minutes at
4jC. Extracts were diluted to 1 mg/ml and 200 ml precleared
with 20 ml of Protein G Agarose. An amount of 0.4 mg of pri-
mary antibody [CtBP (h440) rabbit polyclonal, Santa Cruz
#11390, SP1(PEP2) rabbit polyclonal, Santa Cruz #59,
HDAC2 rabbit polyclonal, Zymed Laboratories, Inc. (South
San Francisco, CA) #51-5100, or rabbit anti hemagglutinin,
Zymed Laboratories, Inc., #71-5500] was added and incu-
bated with rotation at 4jC for 2 hours, before adding 15 ml
of Protein G Agarose and incubating for a further 4 hours
with rotation at 4jC. Beads were pelleted and washed
six times in whole cell lysis buffer. Precipitated proteins
were eluted in 20 ml of elution buffer (glycine, pH 2.5,
0.2 M) and separated by SDS-PAGE. They were transferred
to Millipore nitrocellulose membranes and immunoblotted
with either CtBP (E-12, Santa Cruz #17759) or SP1(PEP2,
Santa Cruz #59). Proteins were visualized with ECL (HRP)
Western blot analysis system (AmershamPharmaciaBiotech).
Results
The Adenoviral Protein, E1A, Activates Both the hTERC
and hTERT Promoters and Is Dependent on an
Intact C-terminal Interacting Domain
Luciferase reporter constructs under control of the hTERT
promoter (pLhTERT1/9) and the hTERC promoter (pLh2923)
were transiently transfected into the bladder carcinoma cell
line, 5637, with various E1A expression constructs. A con-
struct expressing E1A 243R produced a three-fold activation
of the hTERT promoter and a 2.5-fold activation of the
hTERC promoter (Figure 3). Expression of exon 2 of E1A
(amino acids 186–289) alone was sufficient to induce a two-
fold activation in both promoters. In contrast, exon 2 of E1A
had no effect on the SV-40 promoter. Deletion of the CID
from either E1A 243R or exon 2 resulted in complete loss of
activation, demonstrating that the C-terminal interacting
domain is necessary for activation of the telomerase pro-
moters by E1A (Figure 3). Similar results were found in the
lung carcinoma line, A549 (data not shown).
To identify the regions of the promoters involved in activa-
tion by E1A, a series of mutants of the two promoters involving
known regulatory sites was used in transient transfections.
SP1 Sites Are Essential for Activation of the hTERC
Promoter by Exon 2 of E1A
The core promoter of the hTERC gene contains a CCAAT
box, which is essential to promoter function, and four SP1
sites (Figure 1) [35,38]. Luciferase reporter constructs driven
by the hTERC core promoter (pLh2923), the same promoter
where all four SP1 sites had been mutated or where the
CCAAT box had been mutated, were transiently transfected
into 5637 cells with constructs expressing either exon 2 of
E1A or exon 2 with deletion of the CID. Expression of exon
2 of E1A was confirmed by Western blot analysis (data
not shown). Mutation of the CCAAT box abrogated basal
promoter activity and this could not be recovered by co-
expression with E1A (Figure 4A). Mutation of all four SP
Figure 3. Activation of the hTERC and hTERT promoters occurs with E1A
243R and with exon 2 of E1A alone but is dependent on an intact C-terminal
interacting domain. (A) Three micrograms of pLh2923 was cotransfected
with 0.25 g of pML00512S (E1A 243R), and pML00512sD225–238 (243R
with deletion of the CID) or 0.5 g of pcdl 1119 (exon 2 of E1A) and pcdl 1135
(exon 2 with deletion of CID) in 5637 cells as indicated. One microgram of
pGL3-control (SV40) was transfected with 0.5 g of pcdl 1119. Luciferase
activity is expressed as fold induction relative to the pLh2923 and pGL3-
control promoters alone. (B) Three micrograms of pLhTERT1/9 was cotrans-
fected with 1 g of pML00512S, pML00512sD225–238, pcdl 1119, and
pcdl 1135. Luciferase activity is expressed as fold induction relative to the
hTERT1/9 promoter alone. Expression of E1A constructs was checked by
Western blot analysis (not shown).
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sites did not affect basal promoter activity but resulted in
loss of activation by exon 2 of E1A (Figure 4B), demonstrat-
ing that the SP1 sites are essential for activation of hTERC
by E1A and indicating that these are the potential targets for
binding by CtBP.
The E-Boxes Are Not Required for Activation of the
hTERT Promoter by Exon 2 of E1A
The hTERT core promoter contains two E-boxes
(CACGTG), which can bind myc/max and mad/max hetero-
dimers [25,39] as well as five SP1 sites. The initial trans-
fections demonstrating activation by E1A were performed
with the reporter construct pLhTERT1/9 (nucleotides 506
to +33). This construct is 541 bp long but lacks the most
proximal myc binding site. A number of reports demonstrated
the importance of this site [39,40], so two new plasmids
were generated, including this site pLhTERT 24/9 (576 bp,
nucleotides 506 to +70) and pLhTERT 24/25 (276 bp,
nucleotides 206 to +70). The basal activity of pLhTERT
1/9 was lower than that of pLhTERT 24/9, consistent with the
known transactivating activity of the proximal myc box in
some cell types [37] (Figure 5A). The shorter construct
Figure 4. (A) Mutation of the CCAAT box in the hTERC promoter results in
loss of promoter activity. This cannot be rescued by expression of exon 2 of
E1A. Three micrograms of pLh2923 and pLh1011 (hTERCmCCAAT) was
cotransfected with 0.5 g of pcdl 1119 (exon 2 of E1A) and pcdl 1135 (exon 2
with deletion of CID) as indicated and with 2.0 g of the control renilla vector
pac5RL. Luciferase activity is shown relative to renilla activity. (B) Mutation of
all four SP1 sites in the hTERC promoter abrogates activation by exon 2 of
E1A. Three micrograms of pLh2923 and pLh114 (hTERCm4SP1) was
cotransfected with 0.5 g of pcdl 1119 (exon 2 of E1A) and pcdl 1135 (exon 2
with deletion of CID) as indicated and with 2.0 g of the control renilla vector
pac5RL. Luciferase activity is expressed as fold induction relative to the
respective promoter constructs alone. Expression of E1A constructs was
checked by Western blot analysis (not shown).
Figure 5. (A) The 276-bp promoter pLhTERT 24/25 is sufficient for activation
by exon 2 of E1A. Three micrograms of pLhTERT19, pLhTERT24/25, and
pLhTERT24/9 was cotransfected with 0.5 g of pcdl 1119 (exon 2 of E1A) as
indicated. (B)Mutation of the E-boxes reduces basal promoter activity but does
not affect activation of the hTERT promoter by exon 2 of E1A. Three
micrograms of pLhTERT24/25, pLhTERT24/25-1A, pLhTERT24/25-1B, and
pLhTERT24/25-1C was cotransfected with 0.5 g of pcdl 1119 (exon 2 of E1A)
as indicated. Luciferase activity is expressed relative to renilla activity.
Expression of E1A constructs was checked by Western blot analysis (data
not shown). (C) Effect of mutation of SP1 sites in the hTERT promoter on
activation by exon 2 of E1A. Three micrograms of pLhTERT24/9, pLhTERT24/
9-4D, pLhTERT24/9-4E, and pLhTERT24/9-4F was cotransfected with 0.5 g
of pcdl 1119 (exon 2 of E1A) and 0.5 g of the control vector. Mutation of all five
SP1 sites results in loss of promoter activity that cannot be recovered by E1A,
but a construct containing four mutated SP1 sites, with the fifth site just
proximal to the transcriptional start site intact, can still be activated by exon 2 of
E1A. A construct with mutation of the fifth SP1 site alone can still be activated
by exon 2 of E1A. Luciferase activity is expressed relative to renilla activity.
Expression of E1A constructs was checked by Western blot analysis. (D)
Schematic representation of hTERT promoter constructs with mutations. The
SP1 sites are located at the following nucleotides: SP1.1110 to102, SP1.2
88 to 83, SP1.3 56 to 51, SP1.4 36 to 31, and SP1.5 7 to 2, and
the E boxes at 147 to 151 and +45 to +50.
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pLhTERT 24/25 had higher basal activity, suggesting that
repressor sites are present between 206 and 506, con-
sistent with previous reports [41]. All constructs showed a
similar degree of induction with exon 2 of E1A (Figure 5A).
The sites responsible for activation therefore lie within the
proximal 276 bp of the promoter. Mutation of either or both
E-boxes reduced the basal promoter activity as expected but
did not abrogate activation by E1A (Figure 5B), demonstrat-
ing that the E-boxes are not involved in activation by E1A.
Activation of the hTERT Promoter by E1A May Involve the
SP1 Sites
In transient transfections, mutation of all five SP1 sites
(pLhTERT 24/9 4E) abrogated basal promoter activity
(Figure 5C) and exon 2 of E1A was unable to recover even
basal activity so it is not possible to conclude from this
whether the SP1 sites are involved in activation by E1A
as the mutations may have destroyed promoter function.
Mutation of the first four sites (pLhTERT 24/9 4D) reduced
basal promoter activity, but exon 2 of E1A produced a similar
degree induction to the wild-type promoter (Figure 5C). To
test whether the fifth SP1 site was critical in activation by
E1A, this site was mutated independently (pLhTERT 24/9
4F). The basal activity was reduced but induction by E1A
was unchanged (Figure 5C). If the SP1 sites are involved,
then a single functional site is sufficient to allow induction of
the hTERT promoter by exon 2 of E1A.
SP1 is typically an activator of transcription whereas SP3
can act as an activator or repressor. Expression of SP3
represses hTERC promoter activity in 5637 cells (Figure 6B)
as previously reported [35]. An approximately 50% reduction
in activity is also seen with the core hTERT promoter
(pLhTERT 24/25) (Figure 6A). Both promoters are activated
by SP1 and this activation is abrogated by coexpression of
SP3 (Figure 6, C and D). Identification of SP3 as a repressor
of both hTERT and hTERC promoters is in keeping with the
report that SP3 is likely to act as a repressor when multiple
SP sites are present in close proximity [42].
If E1A-induced activation involves the SP1 sites, then
overexpression of SP3 should inhibit this activation. The
SP1 sites are essential for activation of hTERC by E1A
and SP3 reduces activation by exon 2 of E1A as expected
Figure 6. SP3 represses the basal activity of both the hTERC and hTERT promoters and represses activation of the promoters by SP1. (A) Three micrograms of
pLhTERT24/25 was cotransfected with 0.5, 1.0, and 2.0 g of pCMV-SP3 and with 2 g of the control vector pac-5RL. (B) Three micrograms of pLh2923 was co-
transfected with 0.5, 1.0, and 2.0 g of pCMV-SP3 as indicated and with 2 g of the control vector pac-5RL. Luciferase activity is expressed as fold induction rel-
ative to the promoters alone. (C) Three micrograms of pLhTERT24/25 was cotransfected with 2.0 g of pCMV-SP1 and 0.5, 1.0, and 2.0 g of pCMV-SP3. (D) Three
micrograms of pLh2923 was cotransfected with 2.0 g of pCMV-SP1 and 0.5, 1.0, and 2.0 g of pCMV-SP3. Luciferase activity for 5 g of cellular protein is shown.
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(Figure 7A) (equal expression of exon 2 was confirmed by
Western blot analysis). The SP1 sites are essential for the
basal promoter activity of hTERT, which makes it more dif-
ficult to demonstrate their role in activation by E1A; however,
SP3 produced a similar reduction in activation by exon 2 of
E1A (Figure 7B), suggesting that the SP1 sites might be in-
volved in the activation of the hTERT promoter by E1A.
CtBP Represses Activation of the Telomerase Gene
Promoters by Exon 2 of E1A
The transcriptional corepressor, CtBP, binds to the CID
within exon 2 of E1A through a short amino acidmotif, PXDLS
[43,44]. The only other proteins known to bind to this region
are DYRK1A and B [45]. CtBP interacts with a number of
transcriptional regulators through a PXDLS motif and acts
as a corepressor. Because the CID was required for activa-
tion of the telomerase promoters by E1A, the effect of CtBP
itself was investigated.
Expression of CtBP produced a dose-dependent repres-
sion of E1A exon 2–induced expression but had no effect on
the basal promoter activity of either the hTERT or the hTERC
promoter in 5637 cells (Figure 8, A and C). CtBP did not
affect expression levels of exon 2 as assessed by Western
blot analysis (Figure 8, B and D).
The second exon of E1A is able to activate transcription
from a number of unrelated promoters. It may act by seques-
tering CtBP, thereby acting as a functional knockout and
relieving CtBP-mediated repression of transcription [46].
CtBP can be recruited to promoters by a number of different
transcription factors, but no transcription factors with a
classic PXDLS, CtBP binding domain are known to bind to
the telomerase component promoters. However, CtBP can
associate with proteins without a recognizable PXDLS do-
main [36,47–49] and can interact with transcription factors
through adaptor proteins such as CtIP [50].
CtBP Interacts with SP1
To further test our hypothesis that activation of the telo-
merase gene promoters by exon 2 of E1A involves seques-
tration of CtBP from the SP1 sites, we looked for evidence
of an interaction between CtBP with SP1 in coimmune pre-
cipitation reactions. Cell lysates from5637 cells were immuno-
precipitated with CtBP, SP1, HDAC 2, and hemagglutinin
antibodies. CtBP was coimmunoprecipitated with SP1 and
HDAC 2 (Figure 8E ), and SP1 was coimmunoprecipitated
with CtBP and HDAC 2 (Figure 8F ). HDAC 2 was included
as a positive control because interaction between CtBP and
HDAC 2, and HDAC2 and SP1 has already been reported
[51–53]. It is therefore possible that the interaction between
SP1andCtBP is indirect throughanHDAC-containingcomplex.
Discussion
We have demonstrated that the immortalizing adenoviral
protein, E1A, activates both the telomerase gene promoters
in a reporter system. This activation is dependent on an
intact C-terminal interacting domain. The corepressor CtBP
is known to bind to this region and a model has been
proposed whereby exon 2 of E1A is able to sequester CtBP
away from promoters, allowing relief of repression and
upregulation of promoter activity [43,46]. Overexpression
of CtBP alone did not reduce basal activity of either telo-
merase promoter, which could reflect the fact that the
promoters are already maximally occupied by CtBP or in a
repressed state by other mechanisms. Overexpression of
CtBP did, however, interfere with derepression by exon 2
of E1A, consistent with the model of sequestration. Thus,
we have identified CtBP as a potential repressor of tran-
scription at both telomerase gene promoters.
During the preparation of this work, Kirch et al. [54] re-
ported an increase in hTERT promoter activity with E1A and
found that this was reduced on deletion of the N-terminal,
suggesting that exon 1 of E1A can also contribute to the
activation of the hTERT promoter. This is consistent with our
findings because E1A-243R produced a slightly stronger
activation of hTERT than exon 2 alone and some activation
was retained by E1A-243RDCID. However, the N-terminal
is not essential to activation by E1A because we have
Figure 7. SP3 represses activation of the hTERC and hTERT promoters
by exon 2 of E1A. (A) Three micrograms of pLh2923 was cotransfected with
0.5 g of pcdl 1119 (exon 2 of E1A) and 0.5, 1.0, and 2.0 g of pCMV-SP3
as indicated, with 2 g of the control vector pac-5RL. Luciferase activity
normalized to renilla activity is expressed as fold induction relative to the
promoter alone. (B) Three micrograms of pLhTERT24/25 was cotransfected
with 0.5 g of pcdl 1119 (exon 2 of E1A) and 0.5, 1.0, and 2.0 g of pCMV-SP3
as indicated, with 2 g of the control vector pac-5RL. Luciferase activity is
expressed relative to renilla activity. The expression of exon 2 of E1A was
checked by Western blot analysis (not shown).
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demonstrated a continued activation with exon 2 of E1A
alone. They did not investigate the contribution of the
C-terminal interacting domain. Activation by the N-terminal
of E1A may still involve sequestration of CtBP as CtBP can
potentially interact with the N-terminal of E1A through a
CtIP/pRB complex [55].
Both the hTERC and hTERT promoters contain multi-
ple SP1 sites and promoter activity is upregulated by over-
expression of SP1 [35,37,38]. A number of factors including
p53 and the human papilloma viral (HPV) protein, E2, appear
to mediate their effects on hTERT through the SP1 sites
[56,57]. In the hTERT promoter, mutation of each individual
site reduces activity to a varying extent depending on cell
type, but mutation of all five sites results in loss of >90% of
promoter activity [37]. In contrast, mutation of all the SP1
sites in the hTERC promoter does not affect basal transcrip-
tion but does prevent activation by exon 2 of E1A. Because
the SP1 sites are essential for hTERT promoter activity, lack
of activation by exon 2 of E1A when all SP1 sites are mutated
could merely reflect the destruction of essential promoter
architecture rather than a true dependence on the SP1 sites
of E1A activation. However, the fact that SP3 suppresses
activation by exon 2 of E1A supports the involvement of the
SP1 sites in the activation of the hTERT promoter as well.
Furthermore, we have demonstrated a novel interaction
between SP1 and CtBP, demonstrating that activation of
the promoters as a result of sequestration of CtBP from the
SP1 sites is biologically plausible. In normal somatic cells,
there is little or no detectable transcription of hTERT but
relatively higher levels of hTERC, which is consistent with
our findings of continued basal expression of hTERC but
minimal transcription of hTERT in the absence of SP1 sites.
Transcription of both promoters is upregulated in cancer
cells, so activation of transcription through SP1 sites could
be a common mechanism by which both telomerase compo-
nents are upregulated during oncogenesis. In a potential
model activator, SP1 and repressor SP3 containing com-
plexes may compete for SP1 binding sites within the pro-
moters. SP1-dependent activation may also be inhibited
by recruitment of inhibitory CtBP containing complexes. This
inhibition can be relieved as a result of sequestration of
CtBP by exon 2 of E1A.
The mechanism of CtBP-mediated repression is not
fully understood. It interacts with the polycomb proteins
[58] and class I and II HDACs [48,51,59,60], but it can act
in both HDAC-dependent and HDAC-independent manner
[36,47,55,61,62]. It has recently been found within a histone-
modifying complex with methyltransferases (HMTs) as well
as the histone deacetylases HDAC 1 and 2. This CtBP
Figure 8. CtBP reduces activation of both hTERT and hTERC promoters by
exon 2 of E1A and interacts with SP1. (A) Three micrograms of pLh2923
was cotransfected with 0.5 g of pcdl 1119 (exon 2 of E1A) and with 0.25,
0.5, and 1.0 g of 6RcCMV-T7-CtBP in 5637 cells. Luciferase activity is
expressed as fold induction relative to the pLh2923 promoter alone. (B)
Expression of exon 2 of E1A was checked by Western blot analysis to ensure
that loss of activation was not due to loss of expression. sc #430 (E1A)
antibody was used with sc #93 (ERK-1) used to control for protein loading.
Western blot analysis was from one of the experiments shown in Figure 6C.
Lanes 1 and 2, pLh2923 alone; lanes 3 and 4, pLh2923 plus 6RcCMV-T7-
CtBP; lanes 5 and 6, pLh2923 plus pcdl 1119; lanes 7 and 8, plus pcdl
1119 and 6RcCMV-T7-CtBP (0.25 g); lanes 9 and 10, plus pcdl 1119 and
6RcCMV-T7-CtBP (0.5) g; lanes 11 and 12, plus pcdl 1119 and 6RcCMV-
T7-CtBP (1.0 g). (C) Three micrograms of pLhTERT19 was cotransfected
with 0.5 g of pcdl 1119 (exon 2 of E1A) and with 0.125, 0.25, and 0.5 g of
6RcCMV-T7-CtBP in 5637 cells. Luciferase activity is expressed as fold
induction relative to the pLhTERT19 promoter alone. (D) Expression of exon
2 of E1A was checked byWestern blot analysis to ensure that loss of activation
was not due to loss of expression. sc #430 (E1A) antibody was used with sc
#93 (ERK-1) used to control for protein loading. Lanes 1 and 2, pLhTERT19
alone; lanes 3 and 4, pLhTERT19 plus pcdl 1119; lanes 5 and 6, pLhTERT19
plus 6RcCMV-T7-CtBP(0.25 g); lanes 7 and 8, plus pcdl 1119 and 6RcCMV-
T7-CtBP(0.125 g); lanes 9 and 10, plus pcdl 1119 and 6RcCMV-T7-CtBP-
(0.25 g); lanes 11 and 12, plus pcdl 1119 and 6RcCMV-T7-CtBP(0.5 g).
(E) Cell lysates from 5637 cells were immunoprecipitated with CtBP(h440)
rabbit polyclonal, SP1(PEP2) rabbit polyclonal, HDAC2 rabbit polyclonal,
and rabbit anti-HA antibodies using Protein A agarose. Proteins were sep-
arated by SDS-PAGE and blots were probed with CtBP (E-12). Molecular
weight markers are indicated on the left-hand side. Bands corresponding to
48 kDa of CtBP are seenwith pulldown by antibodies to SP1, HDAC2, and CtBP
itself but not to hemagglutinin. (F) Cell lysates from 5637 cells were immuno-
precipitated with CtBP(h440) rabbit polyclonal, SP1(PEP2) rabbit polyclonal,
HDAC2 rabbit polyclonal, and rabbit anti-HA antibodies using Protein A agarose.
Proteins were separated by SDS-PAGE and blots were probed with SP1(PEP2)
rabbit polyclonal. Bands corresponding to 96 and 105 kDa of SP1 are seen with
pulldown by antibodies to CtBP, HDAC2, and SP1 itself but not to hemagglutinin.
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complex is able to convert Lys 9 acetylated histone H3,
which is associated with transcriptionally active chromatin,
to Lys 9 methylated H3, which is associated with a re-
pressive chromatin state. The complex also contained two
chromodomain-containing proteins (HPC2 andCDYL), which
could recognize the methylated Lys 9 and further contribute
to the formation of a local repressive chromatin structure
[52]. Thus, CtBP-mediated repression may result from coor-
dinated stepwise histone modification resulting in a repres-
sive chromatin environment.
Modification of the chromatin environment has also
been implicated in the control of transcription from the hTERT
gene. A number of the transcription factors that associate
with both the hTERT and hTERC promoters are able to inter-
act with histone acetylases (HATs) and histone deacetylases
(HDACs). SP1 can interact with HDAC1 [63] and is found in
multiprotein complexes with p300 and CBP [64,65]. NFY can
also interact with p300 [66], whereas Myc interacts with
TRAPP, which can in turn recruit GCN5 [67]. The repressor
activity of Mad is thought to involve recruitment of the re-
pressor complex Sin 3A, which has HDAC properties and
in turn recruits other histone deacetylases (reviewed in
Refs. [68–71]) and E2F can also recruit complexes contain-
ing HDACs and Sin3B [72]. Inhibition of histone deacetylase
activity with Trichostatin A (TSA) results in an increase in
promoter activity in reporter systems and in the reexpres-
sion of hTERT in some hTERT-negative cells [27,28]. Down-
regulation of hTERT with induced differentiation of HL60
cells is also associated with a decrease in acetylation of H3
and H4 histones [29]. It is of note that the effect of TSA on
the hTERT promoter is also dependent on intact SP1 sites
[28] and we have seen a similar involvement of the SP1 sites
in the activation of the hTERC promoter by TSA (unpublished
data). It is possible that a CtBP complex, associating with the
SP1 sites, represses the telomerase promoters by modifying
chromatin structure. Confirmation of this will require assess-
ment of specific histone modifications at the endogenous
promoters, and this is being investigated in ongoing works.
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